


A. A. El-Khamry, S. A. Shiba, A. A. Shalaby, and A. A. Abd alaha\*

Chemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt

e-mail: abdoelaal@yahoo.com

Received October 31, 2005




The benzoxazinone derivative 2-(6,8-dibromo-4-oxo-4H-benzo[d]-1,3-oxazin-2-yl)-3-(4-methoxyphenyl)acrylonitrile (**1**) has been used as a starting material for preparation of the hitherto unknown pyrazoloquinazolinone and quinazolinone derivatives. Under different conditions the benzoxazinone (**1**) was reacted with hydrazine hydrate to provide the pyrazolocarbonitrile derivative (**2**) and the azine derivative (**3**) and/or the pyrazoloquinazolinone derivative (**4**). When (**4**) was conducted to react either with EAA (ethyl acetoacetate) or Ac<sub>2</sub>O/AcOH (acetic anhydride/acetic acid) mixture or phthalic anhydride/acetic acid mixture, the pyrazoloquinazolinone carbonitrile (**5**), pyrazolo-quinazolinone acetic acid (**6**) or the pyrazoloquinazolinone derivative (**7**) were formed respectively. When (**1**) was reacted with phenylhydrazine, a mixture of the quinazolinone derivative (**8**) and the hydrazone derivative (**9**) were obtained. The benzoxazinone derivative (**1**) was found also to react with benzylamine in ethanol or without solvent to give the quinazolinone derivative (**10**) or the quinazolinone derivative (**11**) respectively. Fusion of (**1**) with ammonium acetate yielded the quinazolinone (**12**), which was methylated to give (**13**) and thiated to the thioquinazolinone derivative (**14**), while reaction of (**1**) with formamide gave the *N*-formylquinazolinone derivative (**15**).


*J. Heterocyclic Chem.*, **43**, 1189 (2006).

The pronounced biological and pharmacological activities as anticonvulsant [1,2], antihistaminic [3,4], antihypertensive [5-8] of these classes of compounds have stimulated the authors to synthesize these compounds. Hydrazinolysis of [9] 2-(6,8-dibromo-4-oxo-4H-benzo[d]-1,3-oxazin-2-yl)-3-(4-methoxyphenyl)acrylonitrile (**1**) with hydrazine hydrate in 1-butanol provided a mixture of 3,5-bis-(4-methoxyphenyl)-1H-pyrazole-4-carbonitrile (**2**) and [10] *N,N*-bis-(4-methoxybenzylidene)hydrazine (**3**).

The following mechanism below summarizes their formation.


However, when the reaction was carried out in ethanol, 5,7-dibromo-2-(4-methoxyphenyl)-9-oxo-1,9-dihydropyrazolo[5,1-*b*]quinazolin-3-carbonitrile (**4**) was obtained in fairly good yield. The structure of (**4**) was further supported by the following chemical proofs. Reaction of (**4**) with EAA (ethyl acetoacetate) yielded 5,7-dibromo-2-(4-methoxyphenyl)-9-oxo-1-(1,3-dioxobutyl)-1,9-dihydro-





pyrazolo[5,1-*b*]quinazolin-3-carbonitrile (5). The pyrazoloquinazoline derivative (4) was reacted with  $\text{Ac}_2\text{O}/\text{AcOH}$  mixture to give 5,7-dibromo-3-cyano-2-(4-methoxyphenyl)-9-oxo-1,2,3,9-tetrahydropyrazolo[5,1-*b*]quinazolin-

benzylamine reacted with (1) to give the quinazolinone derivative (10), while in excess of benzylamine, the dione derivative (11) was obtained according to the following mechanism:



2-acetic acid (6). On the other hand (4) was conducted to react with phthalic anhydride/ $\text{AcOH}$  to give 3-acetyl-5,7-dibromo-2-(4-methoxyphenyl)-3*H*-pyrazolo[5,1-*b*]quinazolin-9-one (7).

Treatment of (1) with ethanolic solution of phenylhydrazine gave a mixture of 6,8-dibromo-4-oxo-3-phenylamino-3,4-dihydroquinazolin-2-yl) acetonitrile (8) and *p*-anisaldehyde phenylhydrazone (9). In contrast to Ismail [11] and our previous results [7,9] aminolysis of benzoxazinone (1) with primary amines depends not only on the type of amine but also on the conditions, beside the nature of group in position-2, since in ethanolic solution,

Fusion of (1) with ammonium acetate gave the quinazolinone derivative (12), whose structure was confirmed by the following chemical proofs: Methylation of (12) with dimethylsulphate furnished 2-(6,8-dibromo-3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)-3-(4-methoxyphenyl)acrylonitrile (13). Thiation of (12) with  $\text{P}_2\text{S}_5$  gave 2-(6,8-dibromo-4-thioxo-3,4-dihydroquinazolin-2-yl)-3-(4-methoxyphenyl)acrylonitrile (14). Formylation of (1) with excess formamide, yielded the *N*-formylquinazolinone derivative (15).




Table 1

Characterization Data of Prepared Compounds

Compd No.	M P °C (colour)	Yield % (solvent)	Mol. For. (M.Wt)	Analysis (Required/found)		
				C	H	N
2	287-90 (Brown)	50 E	C <sub>18</sub> H <sub>15</sub> N <sub>3</sub> O <sub>2</sub> (305.34)	70.80	4.91	4.20
	178-80 (Pale yellow)	40 E	C <sub>16</sub> H <sub>16</sub> N <sub>2</sub> O <sub>2</sub> (268.32)	—	—	—
4	257-60 (Brown)	45 D	C <sub>18</sub> H <sub>10</sub> Br <sub>2</sub> N <sub>4</sub> O <sub>2</sub> (474.11)	45.60	2.12	11.81
	235-37 (Brown)	50 T	C <sub>22</sub> H <sub>14</sub> Br <sub>2</sub> N <sub>4</sub> O <sub>4</sub> (558.19)	47.33	2.52	10.03
6	348-50 (Yellow)	55 B	C <sub>20</sub> H <sub>14</sub> Br <sub>2</sub> N <sub>4</sub> O <sub>4</sub> (534)	44.98	2.64	10.49
	350-52 (Colorless)	40 T/E	C <sub>19</sub> H <sub>13</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>3</sub> (491.17)	45.20	2.25	10.62
8	151-54 (Orange)	45 B	C <sub>18</sub> H <sub>10</sub> Br <sub>2</sub> N <sub>4</sub> O (434.09)	46.46	2.66	8.55
	120-22 (Yellowish white)	40 B	C <sub>16</sub> H <sub>10</sub> Br <sub>2</sub> N <sub>4</sub> O (434.09)	46.75	2.55	8.30
9	120-22 (Yellowish white)	40 B	C <sub>14</sub> H <sub>14</sub> N <sub>2</sub> O (226.28)	44.27	2.32	12.85
	218-20 (Colorless)	55 P	C <sub>25</sub> H <sub>18</sub> Br <sub>2</sub> N <sub>4</sub> O (549.25)	44.60	2.22	12.62
10	218-20 (Colorless)	55 P	C <sub>25</sub> H <sub>18</sub> Br <sub>2</sub> N <sub>4</sub> O (549.25)	74.31	6.23	12.37
	255-57 (Colorless)	65 P	C <sub>15</sub> H <sub>10</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>2</sub> (410.07)	74.50	6.22	12.21
11	255-57 (Colorless)	65 P	C <sub>15</sub> H <sub>10</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>2</sub> (410.07)	54.66	3.12	10.20
	340-43 (Yellow)	90 D	C <sub>18</sub> H <sub>11</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> (461.13)	53.72	3.48	9.98
12	340-43 (Yellow)	90 D	C <sub>18</sub> H <sub>11</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> (461.13)	43.93	2.45	6.80
	270-73 (Yellow)	75 E	C <sub>19</sub> H <sub>13</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> (475.13)	44.90	2.38	6.42
13	270-73 (Yellow)	75 E	C <sub>19</sub> H <sub>13</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> (475.13)	46.85	2.38	9.11
	> 360 (Green)	75 D	C <sub>18</sub> H <sub>11</sub> Br <sub>2</sub> N <sub>3</sub> OS (477.18)	46.94	2.32	9.13
14	> 360 (Green)	75 D	C <sub>18</sub> H <sub>11</sub> Br <sub>2</sub> N <sub>3</sub> OS (477.18)	48.03	2.75	8.84
	240-43 (Green)	80 B	C <sub>19</sub> H <sub>11</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>3</sub> (489.13)	48.51	2.57	8.68
15	240-43 (Green)	80 B	C <sub>19</sub> H <sub>11</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>3</sub> (489.13)	45.30	2.32	8.81
				45.92	2.12	8.25
				46.65	2.26	8.59
				46.91	2.10	8.33

B: Benzene; D: Dioxane; E: Ethanol; P: Petroleum ether (80-100°C); T: Toluene.

Table 2  
<sup>1</sup>H-NMR and MS Data of Prepared Compounds

Compd No.	<sup>1</sup> H-NMR (δ in ppm)	MS (m/z %)	IR cm <sup>-1</sup>		
			ν <sub>NH,OH</sub>	ν <sub>C=N</sub>	ν <sub>C=O</sub>
2	8.22 (broad, NH), 8.10 (d, 4H), 7.18 (d, 4H) and 3.8 (s, 3H)	[M - 2] <sup>+</sup> (303, 8%), 287 (100%), 259 (16%), 231 (19%) and 215 (15%)	3380, 3181	2199	-
3	8.65 (s, 2H), 7.85 (d, 4H), 7.08 (d, 4H) and 3.84 (s, 6H)	[M <sup>+</sup> ] (268, 100%), 240 (23%), 162 (10%), 161 (94.5%) and 134 (30%)	-	-	-
4	8.24 (d, 1H), 8.01 (d, 1H), 8.25 (d, 2H), 7.13 (d, 2H), 7.8 (broad, 1H) and 3.85 (s, 3H)	[M <sup>+</sup> ] (474, 100%), 444 (7%) and 431 (38%)	3303	2199	-
5	-	[M] <sup>+</sup> (558, 27%), 557 (30%), 514 (24%), 394 (27%) and 234 (4%)	3422	2206	1683
6	8.29-8.33 (deformed, d, 2H), 7.97-8.01 (deformed, d, 2H), 7.12-7.17 (deformed, 2H), 3.86 (s, 3H), 1.93 (s, 3H) and 1.21 (s, 1H)	[M - 3] <sup>+</sup> (531, 1.5%), 474 (100%), 473 (11%), 459 (3%) and 444 (4%)	3425	2232	1728
7	—	[M] <sup>+</sup> (491, 19%), 490 (37%) and 104 (100%)	3260	-	1723, 1699
8	—	[M] <sup>+</sup> (434, 8%), 395 (5%), 135 (97%) and 92 (78%)	3430	2209	1685
9	-	[M] <sup>+</sup> (226, 100%), 211 (6%), 195 (1.5%) and 90 (8%)	3313	-	-
10	8.6-8.2 (broad, 3H), 7.85 (deformed 2H), 7.6-7.2 (broad, 9H) and 4.1 (s, 4H)	[M+2] <sup>+</sup> (551, 0.5%), 158 (17%), 106 (100%) and 91 (87%)	3274	2207	1681
11	10.88 (broad, 1H), 8.05 (d, 1H), 8.2 (d, 1H), 7.3 (m, 5H) and 5.1 (s, 2H)	[M] <sup>+</sup> (410, 27%), 393 (8%), 303 (6%), 142 (2%) and 91 (100%)	3355	-	1718, 1661
12	11.8 (hump, 1H), 8.44 & 8.18 (broad 2H), 8.36 (s, 1H), 8.04-8.01 (d, 2H), 7.2 & 7.17 (d, 2H) and 3.8 (s, 3H)	[M+2] <sup>+</sup> (463, 5%), 461 (60%), 460 (100%), 380 (12%) and 277 (26%)	3240	2229	1679
13	—	[M+2] <sup>+</sup> (477, 17%), 476 (24%), 475 (23%), 460 (100%), 445 (12%) and 353 (6%)	-	2218	1659
14	—	[M+1] <sup>+</sup> (478, 13%), 477 (16%), 445 (9%), 444 (17%), 380 (22%), 301 (13%), 184 (19%) and 170 (25%)	3320	2229	-
15	9.04 (s, 1H), 8.35 & 8.18 (deformed 2H), 8.25 (s, 1H), 7.2 & 7.24 (d, 2H), 6.85 & 6.65 (d, 2H) and 3.75 (s, 3H)	[M] <sup>+</sup> (489, 70%), 473 (100%), 448 (22%) and 396 (18%)	-	2206	1710, 1687

## EXPERIMENTAL

Melting points were measured on an electrothermal melting point apparatus and are uncorrected. Elemental analyses were carried out at the Micro-Analytical unit, Cairo University, Giza. Infrared spectra were measured on a Unicam SP-1200 spectrometer using KBr wafer technique. <sup>1</sup>H NMR spectra were measured in DMSO-d<sub>6</sub> on a Varian plus instrument (300 MHz). The mass spectra were determined using HP model MS-5988 at electron energy 70 eV.

3,5-Bis-(4-methoxyphenyl)-1*H*-pyrazole-4-carbonitrile (**2**) and [10] *N,N*-Bis(4-methoxybenzylidene)hydrazine (**3**).

A mixture of benzoxazinone (**1**) (0.01 mol) and hydrazine hydrate (0.01 mol) in 1-butanol (30 mL) was refluxed for 6 h. The solid that formed after concentration of the solvent was collected and crystallized to give (**2**) and (**3**) which were identified by mp and mixed mp with authentic sample.

5,7-Dibromo-2-(4-methoxyphenyl)-9-oxo-1,9-dihydropyrazolo[5,1-*b*]quinazoline-3-carbonitrile (**4**).

A mixture of (**1**) (0.01 mol) and hydrazine hydrate (0.01 mol) in ethanol (30 mL) was refluxed for 5 h. The solid that formed while heating was collected and crystallized to give (**4**).

5,7-Dibromo-2-(4-methoxyphenyl)-9-oxo-1-(1,3-dioxobutyl)-1,9-dihydropyrazolo[5,1-*b*]quinazoline-3-carbonitrile (**5**).

A mixture of (**4**) (0.01 mol) and ethyl acetoacetate (0.01 mol) in ethanol (50 mL) was refluxed for 3 h. The solid that formed after concentration of the solvent was collected and crystallized to give (**5**).

5,7-Dibromo-3-cyano-2-(4-methoxyphenyl)-9-oxo-1,2,3,9-tetrahydropyrazolo[5,1-*b*]quinazolin-2-acetic acid (**6**).

A mixture of (**4**) (0.01 mol) and acetic anhydride (5 mL) in acetic acid (30 mL) was refluxed for 3 h. The solid that formed after concentration of the solvent was collected and crystallized to give (**6**).

3-Acetyl-5,7-dibromo-2-(4-methoxyphenyl)-3*H*-pyrazolo[5,1-*b*]quinazolin-9-one (**7**).

A mixture of (**4**) (0.01 mol) and phthalic anhydride (0.01 mol) in acetic acid (30 mL) was refluxed for 3 h. The solid that formed after concentration of the solvent was collected and crystallized to give (**7**).

(6,8-Dibromo-4-oxo-3-phenylamino-3,4-dihydroquinazolin-2-yl)acetonitrile (**8**) and *p*-Anisaldehyde phenyl hydrazone (**9**).

A mixture of (**1**) (0.01 mol) and phenyl hydrazine (0.01 mol) in ethanol (30 mL) was refluxed for 3 h. The solid that formed

after concentration of the solvent was collected and crystallized to give **(8)** and **(9)**.

2-(3-Benzyl-6,8-dibromo-4-oxo-3,4-dihydroquinazolin-2-yl)-3-(benzylamino)acrylonitrile **(10)**.

A mixture of **(1)** (0.01 mol) and benzyl amine (0.01 mol) in ethanol (50 mL) was refluxed for 5 h. The solid that formed after concentration of the solvent was collected and crystallized to give **(10)**.

3-Benzyl-6,8-dibromo-1*H*-quinazoline-2,4-dione **(11)**.

A mixture of **(1)** (0.01 mol) and benzylamine (20 mL) was refluxed for 3 h. After cooling, the reaction mixture was poured onto ice cold HCl, the solid that formed was collected and crystallized to give **(11)**.

2-(6,8-Dibromo-4-oxo-3,4-dihydroquinazolin-2-yl)-3-(4-methoxyphenyl)acrylonitrile **(12)**.

A mixture of **(1)** (0.01 mol) and ammonium acetate (0.04 mol) was heated in oil bath at 180-190 °C for 3 h. The residue was triturated with warm water, then collected and crystallized to give **(12)**.

2-(6,8-Dibromo-3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)-3-(4-methoxyphenyl)acrylonitrile **(13)**.

A mixture of **(12)** (0.01 mol) and dimethylsulphate (0.01 mol) in sodium hydroxide (50 mL) was refluxed for 5 h. After cooling, the reaction mixture was poured in ice cold hydrochloric acid, the solid formed was collected and crystallized to give **(13)**.

2-(6,8-Dibromo-4-thioxo-3,4-dihydroquinazolin-2-yl)-3-(4-methoxyphenyl)acrylonitrile **(14)**.

A mixture of **(12)** (0.01 mol) and phosphorous pentasulphide (0.02 mol) was heated in a sand bath at 250 °C for 5 h. The solid

that formed after cooling was triturated with boiling water, collected and crystallized to give **(14)**.

2-(6,8-Dibromo-3-formyl-4-oxo-3,4-dihydroquinazolin-2-yl)-3-(4-methoxyphenyl)acrylonitrile **(15)**.

A mixture of **(1)** (0.01 mol) and formamide (30 mL) was refluxed for 3 h. After cooling, the reaction mixture was poured into water, and the solid that formed was collected and crystallized to give **(15)**.

#### REFERENCES

- [1] J. Erusalimsky and R. Franklin, *Experimental Hematology*, **30**, 625-626 (2002).
- [2] A. M. Farghaly, R. Soliman, M. A. Khalil, A. A. Bekhit, and A. El-Din, *Bollettino Chimico Farmaceutico*, **141**, 372-378 (2002).
- [3] D. Bebbington, J. D. Charrier, R. Davies, S. Everitt, and D. Kay, *PCT Int. Appl. WO 02 50, 065 (Cl. C07D 403/12)*, 27 Jun 2002, *US Appl. PV 286, 949*, 27 Apr 2001; 342 pp; *Chem. Abstr.*, **137**, 47221k (2002).
- [4] M. Okano and K. Mori, *PCT Int. Appl. WO 01 72, 710 (Cl. C07 D 215/42)*, 4 Oct 2001, *JP Appl. 2000/336, 464*, 2 Nov 2000; 75 pp; *Chem. Abstr.*, **135**, 288787p (2001).
- [5] A. S. Alyaa, A. E. Abdel Momen, A. S. Sayed, and A. A. Abd elaal, *Archiv. Der Pharmazie*, **333**, 355 (2000).
- [6] A. A. El-Helby, *Egypt Phar., Sci.*, **36**, 287 (1995).
- [7] A. A. El-Khamry, S. El-Nagdy, M. M. Habashy, and F. A. El-Bassiouny, *F Pharmazie*, **44**, 312 (1989).
- [8] A. E. Ossman and S. E. Barakat, *Saudi Pharm. J.*, **2**, 21 (1994).
- [9] H. M. Madkour, S. A. Shiba, H. M. Sayed and A. A. Hamed, *Sulfur Letters*, **24**, 151 (2001).
- [10] J. B. Shoesmith and J. Slater, *J. Chem. Soc.*, **127**, 1490 (1925).
- [11] M. F. Ismail, N. A. Shams, M. R. Salem S. A. and Emara, *J. Org. Chem.*, **84**, 4172 (1983).